Universe Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Sabby Management, Sabby Volatility Warrant Master Fund, and Hal Mintz have jointly disclosed a passive 4.9% beneficial ownership in Universe Pharmaceuticals INC's Ordinary Shares as of December 31, 2025.
NASDAQ
SCHEDULE 13G/A: Anson Funds Management and Affiliates Disclose 0.98% Stake in Universe Pharmaceuticals, Inc.
Anson Funds Management LP and its affiliated entities, including Anson Management GP LLC, Anson Advisors Inc., and key individuals Tony Moore, Amin Nathoo, and Moez Kassam, have disclosed a collective beneficial ownership of 0.98% of Universe Pharmaceuticals, Inc.'s Ordinary Shares.
NASDAQ
Anson Funds Management LP and its affiliates have reported a 9.9% beneficial ownership stake in Universe Pharmaceuticals, Inc., held for ordinary course of business purposes.
NASDAQ
SCHEDULE 13G: Sabby Management and Affiliates Disclose 9.9% Passive Stake in Universe Pharmaceuticals INC
Sabby Management, LLC, Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz have jointly disclosed a 9.9% beneficial ownership stake in Universe Pharmaceuticals INC, held for passive investment purposes.